# RedChemExpress

## Product Data Sheet

HN

ŃН

# Inhibitors • Screening Libraries • Proteins

## Eleven-Nineteen-Leukemia Protein IN-3

Cat. No.:	HY-152471
CAS No.:	2894121-83-4
Molecular Formula:	$C_{28}H_{27}N_5O_2$
Molecular Weight:	465.55
Target:	Epigenetic Reader Domain
Pathway:	Epigenetics
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIV	VITY							
Description	Eleven-Nineteen-Leukemia Protein IN-3 is an orally active inhibitor of ENL YEATS domain with an IC <sub>50</sub> value of 15.4 nM. Eleven-Nineteen-Leukemia Protein IN-3 down-regulates MYC expression through ENL in cells and can enhances the thermal stability of ENL protein in vitro <sup>[1]</sup> .							
IC <sub>50</sub> & Target	Eleven-Nineteen-Leukemia YEATS domain 15.4 nM (IC <sub>50</sub> )							
In Vitro	Eleven-Nineteen-Leukemia Protein IN-3 (Compound 28) has significant inhibitory effect on MV4-11 and MOLM-13 cell line with IC <sub>50</sub> values of 4.8 μM and 8.3 μM, respectively <sup>[1]</sup> . Eleven-Nineteen-Leukemia Protein IN-3 (5 μM; 6 h) significantly improves the thermal stability of endogenous ENL prote but has insignificant effect on the thermal stability of GAS41 protein. Eleven-Nineteen-Leukemia Protein IN-3 can effect inhibits the growth of MOLM-13 cells <sup>[1]</sup> . Eleven-Nineteen-Leukemia Protein IN-3 (5 μM; 72 h) inhibits the key oncogene MYC (about 50 %). Eleven-Nineteen-Leuk Protein IN-3 can further down-regulates the expression of MYC in the ENL target gene when works with JQ-1 (HY-13030) MCE has not independently confirmed the accuracy of these methods. They are for reference only. RT-PCR <sup>[1]</sup>							
	Concentration:	5 μM.						
	Incubation Time:	72 h.						
	Result:	Showed inhibitory for MYC.						
In Vivo	Eleven-Nineteen-Leukemia Protein IN-3 (Compound 28) (30 mg/kg; p.o.; single dose) shows oral exposure characteristics <sup>[1]</sup> . Eleven-Nineteen-Leukemia Protein IN-3 (5 mg/kg; i.v.; single dose) highly exposes in vivo <sup>[1]</sup> . Pharmacokinetic (PK) study in Male BALB/c mice <sup>[1]</sup>							
	Administration $t_{1/2}$ (h)	$T_{max}$ (h) $C_{max}$ (ng/mL) $AUC_{0-t}$ $AUC_{0-\infty}$ $MRT_{0-\infty}$ (h) (h•ng/mL) (h•ng/mL)						

p.o.	5.2	0.5	71.8	257	272	5.5				
Administration	t <sub>1/2</sub> (h)	AUC <sub>0-t</sub> (h•ng/mL)	AUC <sub>0-∞</sub> (h•ng/mL)	V <sub>ss</sub> (L/kg)	CL (mL/min/kg)	$MRT_{0-\infty}\left(h\right)$	F (%)			
i.v.	4.0	8290	8690	0.8	9.6	1.3	0.5			
MCE has not indep	pendently c	onfirmed the accu	uracy of these m	ethods. They a	re for reference c	only.				
Animal Model:		Male BALB/c mice <sup>[1]</sup> .								
Dosage:		30 mg/kg.								
Administration:		Oral gavage; single dose.								
Result:		Showed an oral activity.								
Animal Model:		Male BALB/c mice <sup>[1]</sup> .								
Dosage:		5 mg/kg.								
Administration:		Intravenous injection; single dose.								
Result:		Exhibited efficacy.								

### REFERENCES

[1]. Guo S, et al. Design, synthesis of novel benzimidazole derivatives as ENL inhibitors suppressing leukemia cells viability via downregulating the expression of MYC. Eur J Med Chem. 2023 Feb 15;248:115093.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909

5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA